LUC00125I2 - - Google Patents

Download PDF

Info

Publication number: LUC00125I2
Authority: LU; Luxembourg
Prior art keywords: compound; acetylaminoisoindoline; methylsulfonylethyl; dione; solvate
Prior art date: 2002-03-20

Application number

LU00125C

Other languages

English (en)

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-20

Filing date

2019-06-14

Publication date

2019-12-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28457137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00125(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2019-06-14 Application filed by Celgene Corp filed Critical Celgene Corp

2019-06-18 Publication of LUC00125I1 publication Critical patent/LUC00125I1/fr

2019-12-24 Publication of LUC00125I2 publication Critical patent/LUC00125I2/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Virology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Hematology (AREA)
Psychiatry (AREA)
Otolaryngology (AREA)
Tropical Medicine & Parasitology (AREA)
Gastroenterology & Hepatology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)

LU00125C 2002-03-20 2019-06-14 LUC00125I2 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US36651502P	2002-03-20	2002-03-20
US43845003P	2003-01-07	2003-01-07
EP09003138.6A EP2074995B1 (fr)	2002-03-20	2003-03-20	(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: leurs procedes d'utilisation et leurs compositions
EP03721414A EP1485087B1 (fr)	2002-03-20	2003-03-20	(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione pour le traitement du psoriasis par administration orale
PCT/US2003/008738 WO2003080049A1 (fr)	2002-03-20	2003-03-20	(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: leurs procedes d'utilisation et leurs compositions

Publications (2)

Publication Number	Publication Date
LUC00125I1 LUC00125I1 (fr)	2019-06-18
LUC00125I2 true LUC00125I2 (fr)	2019-12-24

Family

ID=28457137

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU00125C LUC00125I2 (fr)	2002-03-20	2019-06-14

Country Status (23)

Country	Link
US (14)	US6962940B2 (fr)
EP (9)	EP2311453B1 (fr)
JP (4)	JP2005525386A (fr)
KR (6)	KR101104991B1 (fr)
CN (2)	CN101683334A (fr)
AT (1)	ATE440599T1 (fr)
AU (1)	AU2003224729C1 (fr)
BE (1)	BE2019C008I2 (fr)
CA (2)	CA2479666C (fr)
CY (6)	CY1109380T1 (fr)
DE (1)	DE60328974D1 (fr)
DK (6)	DK2420490T3 (fr)
ES (8)	ES2742729T3 (fr)
FR (1)	FR19C1046I2 (fr)
HU (5)	HUE045489T2 (fr)
IL (3)	IL164147A0 (fr)
LU (1)	LUC00125I2 (fr)
MX (2)	MXPA04009075A (fr)
NL (1)	NL300994I2 (fr)
NZ (1)	NZ535798A (fr)
PT (6)	PT2223687T (fr)
SI (5)	SI2223687T1 (fr)
WO (1)	WO2003080049A1 (fr)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0918746B1 (fr) *	1996-08-12	2003-04-09	Celgene Corporation	Agents immunotherapiques et leur utilisation pour faire baisser les teneurs en cytokines
US8030343B2 (en) *	2000-06-08	2011-10-04	Celgene Corporation	Pharmaceutically active isoindoline derivatives
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en) *	2002-03-20	2007-10-02	Celgene Corporation	Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
CA2379887C (fr) *	2002-04-09	2004-01-20	Bernard Charles Sherman	Comprimes stables contenant de la simvastatine
US20100129363A1 (en) *	2002-05-17	2010-05-27	Zeldis Jerome B	Methods and compositions using pde4 inhibitors for the treatment and management of cancers
CN1668296A (zh) *	2002-05-17	2005-09-14	细胞基因公司	使用选择性细胞因子抑制性药物用于治疗和控制癌症和其它疾病的方法及组合物
EP1551385A4 (fr) *	2002-10-15	2008-10-22	Celgene Corp	Medicaments selectifs inhibiteurs des cytokines pour le traitement de syndromes myelodysplastiques
US20050203142A1 (en) *	2002-10-24	2005-09-15	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) *	2002-10-24	2004-05-06	Zeldis Jerome B.	Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US7776907B2 (en)	2002-10-31	2010-08-17	Celgene Corporation	Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
KR20090048520A (ko)	2002-11-06	2009-05-13	셀진 코포레이션	암 및 다른 질환의 치료 및 관리를 위한 선택적 시토킨 억제 약물의 사용 방법 및 그 조성물
BR0316002A (pt) *	2002-11-06	2005-09-13	Celgene Corp	Métodos de tratar ou prevenir e controlar uma doença mieloproliferativa, de reduzir ou evitar de um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica e kit
BR0316259A (pt) *	2002-11-18	2005-10-04	Celgene Corp	Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
CA2506442A1 (fr) *	2002-11-18	2004-07-01	Celgene Corporation	Compositions comprenant un (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide et methodes d'utilisation de ces compositions
US20040175382A1 (en) *	2003-03-06	2004-09-09	Schafer Peter H.	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
MXPA05009435A (es) *	2003-03-06	2005-11-23	Celgene Corp	Metodos de uso y composiciones que contienen medicamentos inhibidores selectivos de citocina para el tratamiento y manejo de alteraciones del sistema nervioso central.
CN1767827A (zh) *	2003-03-31	2006-05-03	协和发酵工业株式会社	肺部疾病的治疗及/或预防剂
CA2543132A1 (fr) *	2003-10-23	2005-05-19	Celgene Corporation	Procedes d'utilisations et compositions comprenant des medicaments selectifs inhibiteurs de la cytokine utilises dans le traitement, la modification et la gestion de la douleur
US20050142104A1 (en) *	2003-11-06	2005-06-30	Zeldis Jerome B.	Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
AU2004288715A1 (en) *	2003-11-06	2005-05-26	Celgene Corporation	Methods of using and compositions comprising a JNK inhibitor for the treatment and management of asbestos-related diseases and disorders
JPWO2005056009A1 (ja) *	2003-12-12	2007-07-05	協和醗酵工業株式会社	肺疾患治療剤
CA2561513C (fr)	2004-03-29	2019-02-26	University Of South Florida	Traitement efficace des tumeurs et du cancer a l'aide de la triciribine et de composes associes
US20100028339A1 (en)	2004-03-29	2010-02-04	Cheng Jin Q	Compositions including triciribine and trastuzumab and methods of use thereof
US20100009928A1 (en)	2004-03-29	2010-01-14	Cheng Jin Q	Compositions including triciribine and taxanes and methods of use thereof
US20110008327A1 (en)	2004-03-29	2011-01-13	Cheng Jin Q	Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009929A1 (en)	2004-03-29	2010-01-14	Cheng Jin Q	Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100173864A1 (en)	2004-03-29	2010-07-08	Cheng Jin Q	Compositions including triciribine and one or more platinum compounds and methods of use thereof
EP1744748A4 (fr) *	2004-04-14	2009-08-12	Celgene Corp	Procedes d'utilisation et compositions comprenant des medicaments d'inhibition selective de cytokine, pour traiter et controler des syndromes myelodysplasiques
CA2563377A1 (fr) *	2004-04-23	2005-11-03	Celgene Corporation	Procede d'utilisation de modulateurs de pde4 et compositions les renfermant pour le traitement et la gestion de l'hypertension pulmonaire
JP2007536221A (ja) *	2004-05-05	2007-12-13	セルジーン・コーポレーション	骨髄増殖性疾患を治療及び管理するための選択的サイトカイン阻害薬の使用方法及びそれを含む組成物
WO2005108353A2 (fr) *	2004-05-06	2005-11-17	Ceptor Corporation	Composes destines a traiter des maladies neurologiques, des maladies otologiques ou des maladies ophtalmologiques et leurs methodes d'utilisation
GB0410103D0 (en) *	2004-05-06	2004-06-09	Biolipox Ab	New method
US20070190070A1 (en) *	2004-09-03	2007-08-16	Zeldis Jerome B	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
BRPI0519030A2 (pt) *	2004-12-13	2008-12-23	Celgene Corp	mÉtodos de tratamento, prevenÇço, ou controle de inflamaÇço das vias aÉreas e de uma doenÇa ou distérbio das vias aÉreas ou pulmonar, e, composiÇço farmacÊutica
BRPI0612803A2 (pt) *	2005-06-30	2012-10-02	Celgene Corp	processo para preparar um composto
US20080138295A1 (en) *	2005-09-12	2008-06-12	Celgene Coporation	Bechet's disease using cyclopropyl-N-carboxamide
EP2218442A1 (fr)	2005-11-09	2010-08-18	CombinatoRx, Inc.	Procédés, compositions et kits pour le traitement des maladies ophthalmiques
CN1870631B (zh) *	2005-11-11	2010-04-14	华为技术有限公司	媒体网关的门控方法
US20070155791A1 (en) *	2005-12-29	2007-07-05	Zeldis Jerome B	Methods for treating cutaneous lupus using aminoisoindoline compounds
US20080103086A1 (en) *	2006-10-25	2008-05-01	Jeon-Soo Shin	Methods for the treatment of diseases associated with the secretion of hmgb1
TW200920381A (en) *	2007-07-17	2009-05-16	Combinatorx Inc	Treatments of B-cell proliferative disorders
US20090047243A1 (en) *	2007-07-17	2009-02-19	Richard Rickles	Combinations for the treatment of b-cell proliferative disorders
US20090081173A1 (en) *	2007-08-10	2009-03-26	The Board Of Regents Of The University Of Texas System	Methods and compositions involving bacteriophage isolates
WO2009120296A1 (fr) *	2008-03-24	2009-10-01	Celgene Corporation	Traitement du psoriasis ou du rhumatisme psoriasique par le cyclopropyl-n-{2-{(1s)-1-(3-éthoxy-4-méthoxyphényl)-2-(méthylsulfonyl)éthyl]-3-oxoisoindoline-4-yl}carboxamide
CN102898349A (zh) *	2008-03-27	2013-01-30	细胞基因公司	包含一种化合物的固体形式、其组合物及其用途
PL2276483T3 (pl) *	2008-03-27	2014-09-30	Celgene Corp	Stałe postacie zawierające (+)-2-[1-(3-etoksy-4-metoksyfenylo)-2-metylosulfonyloetylo]-4-acetyloaminoizoindolino-1,3-dion, kompozycje je zawierające i ich zastosowania
EP2687213B1 (fr)	2008-03-27	2019-01-23	Celgene Corporation	Formes solides comprenant de la (+)-2-[1-(3-éthoxy-4-méthoxyphényl)-2-méthylsulfonyléthyl]-4-acétylaminoisoindoline-1,3-dione, leurs compositions, et utilisations associées
CN102702070A (zh) *	2008-03-27	2012-10-03	细胞基因公司	包含(+)-2-[1-(3-乙氧基-4-甲氧基苯基)-2-甲基磺酰基乙基]-4-乙酰基氨基异吲哚啉-1,3-二酮的固体形式、其组合物及其用途
US8053364B2 (en) *	2008-05-01	2011-11-08	Intermolecular, Inc.	Closed-loop sputtering controlled to enhance electrical characteristics in deposited layer
WO2009151569A2 (fr) *	2008-06-09	2009-12-17	Combinatorx, Incorporated	Agonistes des récepteurs bêta-adrénergiques utilisables pour le traitement des troubles prolifératifs des lymphocytes b
KR20110073459A (ko) *	2008-09-01	2011-06-29	미쓰비시 디지털 전자 아메리카, 인크.	텔레비젼 시청을 향상시키기 위한 시스템 및 방법
US20100186234A1 (en) *	2009-01-28	2010-07-29	Yehuda Binder	Electric shaver with imaging capability
MY160002A (en) *	2009-02-10	2017-02-15	Celgene Corp	Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
CN107964016B (zh)	2009-05-14	2021-10-01	天津合美医药科技有限公司	噻吩衍生物
US20110020293A1 (en) *	2009-07-21	2011-01-27	Abt Holding Company	Use of Stem Cells to Reduce Leukocyte Extravasation
CN102053449A (zh) *	2009-10-28	2011-05-11	中国科学院福建物质结构研究所	一种谷氨酸衍生的手性金属-有机非线性光学材料
CN102053448A (zh) *	2009-10-28	2011-05-11	中国科学院福建物质结构研究所	一种硝基苯胺类手性非线性光学材料
WO2011059931A2 (fr) *	2009-11-10	2011-05-19	Celgene Corporation	Nanosuspension d'un médicament médiocrement soluble par un procédé de microfluidisation
WO2011127019A2 (fr)	2010-04-07	2011-10-13	Celgene Corporation	Méthodes de traitement d'une infection respiratoire d'origine virale
CN103026229B (zh)	2010-06-15	2016-03-30	细胞基因公司	用于治疗银屑病的生物标志物
WO2012083017A2 (fr)	2010-12-16	2012-06-21	Celgene Corporation	Formes posologiques pour des médicaments médiocrement solubles administrés par voie orale à libération contrôlée et leurs utilisations
US9532977B2 (en)	2010-12-16	2017-01-03	Celgene Corporation	Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2012083153A1 (fr) *	2010-12-16	2012-06-21	Nektar Therapeutics	Composés comprenant une fraction apremilast et contenant un oligomère
US8853175B2 (en)	2011-01-10	2014-10-07	Celgene Corporation	Phenethylsulfone isoindoline derivatives and their use
ES2632979T3 (es)	2011-01-10	2017-09-18	Celgene Corporation	Formas de dosificación oral de {2-[(1S)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil]-3-oxo-2,3-dihidro-1H-isoindol-4-il}-amida de ácido ciclopropanocarboxílico
US9045417B2 (en)	2011-01-14	2015-06-02	Celgene Corporation	Isotopologues of isoindole derivatives
US9387195B2 (en)	2011-03-07	2016-07-12	Celgene Corporation	Methods for treating diseases using isoindoline compounds
EP2701701B1 (fr) *	2011-04-28	2018-01-24	Celgene Corporation	Méthodes et compositions utilisant des inhibiteurs de pde4 pour le traitement et la gestion de maladies autoimmunes et inflammatoires
SMT202000339T1 (it) *	2011-12-27	2020-07-08	Amgen Europe Gmbh	FORMULAZIONI DI (+)-2-[1-(3-ETOSSl-4-METOSSI-FENIL)-2-METANSOLFONIL-ETIL]-4-ACETILAMMINOISOINDOLIN-1,3-DIONE
WO2013119607A2 (fr)	2012-02-08	2013-08-15	Celgene Corporation	Formulations à libération modifiée à base de (+)-2-[1-(3-éthoxy-4-méthoxy-phényl)-2-méthanesulfonyl-éthyl]-4-acétyl aminoisoindoline-1,3-dione
AR090100A1 (es)	2012-02-21	2014-10-22	Celgene Corp	Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
US8981117B2 (en)	2012-09-14	2015-03-17	Celgene Corporation	Processes for the preparation of isoindole compounds and isotopologues thereof
EP2916869A1 (fr) *	2012-11-09	2015-09-16	Celgene Corporation	Méthodes de traitement de la perte osseuse
CN105050624A (zh)	2013-03-14	2015-11-11	细胞基因公司	利用阿普斯特来治疗银屑病关节炎的方法
NZ628329A (en) *	2013-06-17	2017-12-22	Celgene Corp	Formulations of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
KR101561828B1 (ko)	2013-08-23	2015-10-20	주식회사 아미노로직스	α-아미노산의 라세미화 방법
EP3096749B1 (fr) *	2014-01-24	2019-05-15	Celgene Corporation	Méthodes de traitement de l'obésité à l'aide d'aprémilast
JP2014114308A (ja) *	2014-01-31	2014-06-26	Celgene Corp	（＋）−２−［１−（３−エトキシ−４−メトキシフェニル）−２−メチルスルホニルエチル］−４−アセチルアミノイソインドリン−１，３−ジオンを含む固形物形態、その組成物およびその使用
CN103864670B (zh) *	2014-03-17	2015-08-26	苏州明锐医药科技有限公司	阿普司特的制备方法
IN2014MU01283A (fr)	2014-04-04	2015-10-09	Cadila Healthcare Ltd
US9994522B2 (en)	2014-05-11	2018-06-12	Mapi Pharma Ltd.	Amorphous form of apremilast
MX2016014770A (es)	2014-05-12	2017-05-25	Summit Mining Int Inc	Proceso de lixiviado de salmuera para la recuperacion de metales valiosos de materiales de oxido.
ES2751773T3 (es) *	2014-05-15	2020-04-01	Amgen Europe Gmbh	Uso de inhibidores pde4 y combinaciones de los mismos para el tratamiento de la fibrosis quística
US20170087129A1 (en)	2014-05-16	2017-03-30	Celgene Corporation	Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
EP2949645A1 (fr) *	2014-05-28	2015-12-02	LEK Pharmaceuticals d.d.	Procédés de préparation de composés ß-aminosulfone
JP6687550B2 (ja)	2014-06-23	2020-04-22	セルジーンコーポレイション	肝疾患又は肝機能異常を治療するためのアプレミラスト
CN105294534B (zh) *	2014-07-15	2020-04-10	上海优拓医药科技有限公司	制备阿普司特及其中间体的产业化方法
EP3174999A1 (fr)	2014-07-29	2017-06-07	Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca	Diagnostic différentiel et choix de thérapie pour la polyarthrite rhumatoïde et l'arthrite psoriasique
EP3188745A1 (fr)	2014-08-15	2017-07-12	Celgene Corporation	Dosage d'aprémilast pour le traitement de maladies améliorées par l'inhibition de pde4
CN105622380B (zh) *	2014-10-29	2020-06-30	南京安源生物医药科技有限公司	一种阿普斯特的制备方法及其中间体
CN105588886B (zh) *	2014-11-18	2020-01-31	重庆医药工业研究院有限责任公司	一种采用液相色谱法测定阿普斯特及其制剂中杂质的方法
EP3034496A1 (fr)	2014-12-18	2016-06-22	LEK Pharmaceuticals d.d.	Nouveaux solvates de n-[2-[(1s)-1-(3-ethoxy-4-méthoxyphényl)-2-(méthylsulfonyl)éthyl]-2,3-dihydro-1,3-dioxo-1h-isoindol-4-yl] acétamide
CN104529869B (zh) *	2014-12-19	2017-06-13	苏州亚宝药物研发有限公司	一种 (s)‑2‑[1‑(3‑乙氧基‑4‑甲氧基苯基)‑2‑甲磺酰基乙基]‑4‑乙酰基氨基异吲哚啉‑1,3‑二酮异构体的制备方法
WO2016135755A1 (fr)	2015-02-27	2016-09-01	Mylan Laboratories Limited	Aprémilast amorphe, pré-mélanges correspondant et nouvelles formes cristallines d'aprémilast
CN104803906A (zh) *	2015-03-17	2015-07-29	南京新伟方医药科技有限公司	化合物及其制备方法和用途
WO2016146990A1 (fr)	2015-03-19	2016-09-22	Cipla Limited	Procédé amélioré pour la préparation d'aprémilast
EP3280701B1 (fr)	2015-04-09	2019-10-16	Zentiva K.S.	Procédé de résolution chirale de l'intermédiaire clé de la synthèse d'aprémilast et son utilisation pour la préparation d'aprémilast pur
CN106146384B (zh) *	2015-04-23	2020-09-22	石药集团中奇制药技术（石家庄）有限公司	一种高光学纯度的阿普司特的制备方法、所得产品及其应用
EP3286168A1 (fr)	2015-04-24	2018-02-28	Zentiva K.S.	Forme solide d'aprémilast et un procédé pour sa préparation
US10370329B2 (en) *	2015-04-27	2019-08-06	Mylan Laboratories Limited	Process for the enantiomeric resolution of apremilast intermediates
CN104945306B (zh) *	2015-05-25	2017-07-21	山东铭康医药技术有限公司	制备光学纯阿普斯特的方法
MX2017015151A (es)	2015-05-26	2018-08-15	Lupin Ltd	Un proceso mejorado para la preparación de apremilast y novedosos polimorfos del mismo.
CZ2015383A3 (cs)	2015-06-05	2016-12-14	Zentiva, K.S.	Způsob přípravy klíčového intermediátu apremilastu, využívající enzymatické štěpení racemických aminů
EP3106457A1 (fr)	2015-06-15	2016-12-21	LEK Pharmaceuticals d.d.	Nouvelle voie synthetique vers l'apremilast
CN105111127B (zh) *	2015-08-20	2019-02-19	济南纽华医药科技有限公司	阿普斯特无定形及其制备方法
WO2017033116A1 (fr)	2015-08-26	2017-03-02	Glenmark Pharmaceuticals Limited	Procédé de préparation d'aprémilast
US10544097B2 (en)	2015-08-27	2020-01-28	Msn Laboratories Private Limited	Solid state forms of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide and process for preparation thereof
US9765026B2 (en)	2015-08-28	2017-09-19	Scinopharm Taiwan, Ltd.	Forms of apremilast and the process of making the same
EP3144393A1 (fr)	2015-09-18	2017-03-22	LEK Pharmaceuticals d.d.	Voie synthétique vers l'apremilast
WO2017059040A1 (fr) *	2015-09-29	2017-04-06	Pliva Hrvatska D.O.O.	Procédés de préparation d'aprémilast, et ses intermédiaires
CN105218428A (zh) *	2015-10-20	2016-01-06	南京美嘉宁逸医药研究开发有限公司	一种高手性纯度的阿普斯特的制备方法
US10682336B2 (en)	2015-10-21	2020-06-16	Amgen Inc.	PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)
EP3373916A1 (fr)	2015-11-11	2018-09-19	Celgene Corporation	Formes pharmaceutiques orales à libération contrôlée de médicaments faiblement solubles et leurs utilisations
WO2017085568A1 (fr)	2015-11-19	2017-05-26	Alembic Pharmaceuticals Limited	Procédé amélioré et nouvelle forme polymorphe d'aprémilast
CN105348172B (zh) *	2015-12-04	2017-11-14	新发药业有限公司	(s)‑1‑(4‑甲氧基‑3‑乙氧基)苯基‑2‑甲磺酰基乙胺的制备及阿普斯特的制备方法
EP3181549A1 (fr)	2015-12-17	2017-06-21	Zaklady Farmaceutyczne Polpharma SA	Procédé de préparation de l'apremilast
CN105486785A (zh) *	2015-12-23	2016-04-13	成都百裕金阁莱药业有限公司	阿普斯特中对映异构体杂质的检测方法
CZ20165A3 (cs)	2016-01-06	2017-07-19	Zentiva, K.S.	Způsoby přípravy amorfního apremilastu
WO2017179065A1 (fr)	2016-04-15	2017-10-19	Davuluri Ramamohan Rao	Procédé amélioré pour la préparation d'aprémilast
WO2017196192A1 (fr)	2016-05-12	2017-11-16	Zaklady Farmaceutyczne Polpharma Sa	Formes cristallines de l'aprémilast
WO2017216738A1 (fr)	2016-06-15	2017-12-21	Torrent Pharmaceuticals Limited	Compositions topiques d'apremilast
US10196355B2 (en)	2016-06-20	2019-02-05	Johnson Matthey Public Limited Company	Forms of apremilast
CN106187857B (zh)	2016-06-30	2021-04-06	浙江华海药业股份有限公司	一种制备阿普斯特的方法
IT201600083132A1 (it) *	2016-08-05	2018-02-05	Dipharma Francis Srl	Procedimento per la preparazione di un inibitore della fosfodiesterasi 4
WO2018086473A1 (fr) *	2016-11-09	2018-05-17	广东东阳光药业有限公司	Eutectique d'aprémilast et son procédé de préparation
EP3339292A1 (fr)	2016-12-23	2018-06-27	Zaklady Farmaceutyczne Polpharma SA	Co-cristaux d'apremilast
WO2018138737A1 (fr) *	2017-01-27	2018-08-02	Sarudbhava Formulations Private Limited	Compositions thérapeutiques topiques d'aprémilast
CN107445875A (zh) *	2017-03-22	2017-12-08	陕西科技大学	一种用于制备阿普斯特的高纯度中间体的手性拆分方法
SI3606908T1 (sl) *	2017-04-04	2020-10-30	Quimica Sintetica, S.A.	Delitev racemičnih beta-aminosulfonskih spojin
US10919855B2 (en)	2017-05-04	2021-02-16	Unichem Laboratories Ltd	Process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4yl]acetamide
US20200254093A1 (en)	2017-09-14	2020-08-13	Glaxosmithkline Intellectual Property Development Limited	Combination treatment for cancer
CN107721902A (zh) *	2017-11-08	2018-02-23	中国科学院上海药物研究所	阿普斯特与烟酰胺的共结晶及其制备方法和应用
CN111821297A (zh) *	2019-04-16	2020-10-27	天津合美医药科技有限公司	异吲哚啉衍生物用于治疗免疫球蛋白E（IgE）介导的疾病的应用
CN111821299A (zh) *	2019-04-16	2020-10-27	天津合美医药科技有限公司	噻吩衍生物用于治疗免疫球蛋白E（IgE）介导的疾病的应用
US11357775B2 (en) *	2019-04-30	2022-06-14	Celgene Corporation	Combination therapies comprising apremilast and Tyk2 inhibitors
SG11202112043PA (en)	2019-04-30	2021-11-29	Celgene Corp	Combination therapies comprising apremilast and tyk2 inhibitors
DE112020000136T5 (de)	2019-08-08	2021-07-29	Google Llc	Browserverlauf mit geringer Entropie für die Quasi-Personalisierung von Inhalten
US11194866B2 (en)	2019-08-08	2021-12-07	Google Llc	Low entropy browsing history for content quasi-personalization
TWI733294B (zh)	2019-12-30	2021-07-11	國立臺灣師範大學	製備阿普斯特片之方法
CN115397819A (zh) *	2020-02-24	2022-11-25	苏州隆博泰药业有限公司	Pde4抑制剂化合物及其医药用途
EP3929179A1 (fr)	2020-06-22	2021-12-29	Biohorm, S.L.	Composés anti-inflammatoires et leurs procédés de fabrication
CN112220785B (zh) *	2020-09-22	2021-12-31	北京鑫开元医药科技有限公司	一种pde4抑制剂药物组合物及其制备方法与用途
KR20220047105A (ko)	2020-10-08	2022-04-15	주식회사 엔비피헬스케어	아프레밀라스트를 함유하는 약학 조성물
KR20230157936A (ko) *	2020-12-14	2023-11-17	바이오테릭스, 인코포레이티드	Pde4 분해인자, 약제학적 조성물, 및 치료학적 적용
CN115068467A (zh) *	2021-03-15	2022-09-20	中国医学科学院药物研究所	穿心莲内酯作为ltb4受体抑制剂的医药用途
CN114790164B (zh)	2021-08-13	2022-12-27	苏州璞正医药有限公司	一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途
EP4183389A1 (fr)	2021-11-18	2023-05-24	KRKA, d.d., Novo mesto	Composition pharmaceutique comprenant de l'aprémilast
WO2023105286A1 (fr)	2021-12-06	2023-06-15	My Personal Therapeutics Ltd	Polythérapie contre le cancer
JP2024544720A (ja) *	2021-12-23	2024-12-03	アムジェンインコーポレイテッド	アプレミラストの経口懸濁液
GB202306663D0 (en)	2023-05-05	2023-06-21	Union Therapeutics As	Combination therapy

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US366515A (en)		1887-07-12		Stove-pipe
US3031450A (en)	1959-04-30	1962-04-24	Thomae Gmbh Dr K	Substituted pyrimido-[5, 4-d]-pyrimidines
US3322755A (en)	1964-03-10	1967-05-30	Boehringer Sohn Ingelheim	Basic-substituted 1, 2, 3, 4-tetrahydropyrimido [5, 4-d]-pyrimidines
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
JPS4966691A (fr)	1972-10-30	1974-06-27
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US3820636A (en) *	1973-08-16	1974-06-28	Deere & Co	Self-adjusting control linkage for an external band brake
US4162316A (en)	1975-03-12	1979-07-24	Dainippon Pharmaceutical Co., Ltd.	1-Substituted-4-(1,2-diphenylethyl)piperazine derivatives and compositions containing the same
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4001237A (en)	1976-02-18	1977-01-04	Bristol-Myers Company	Oxazole, isoxazole, thiazole and isothiazole amides
US4060615A (en)	1976-02-18	1977-11-29	Mead Johnson & Company	2-Piperazinyl-6,7-dimethoxyquinazolines
US4001238A (en)	1976-02-18	1977-01-04	Bristol-Myers Company	1,3,4-oxadiazole amides
US4047404A (en)	1976-11-17	1977-09-13	Tanno Senshoku Kogyo Co., Ltd.	Printed fabric washing apparatus
US4101548A (en)	1977-02-22	1978-07-18	Bristol-Myers Company	1,2,3-Thiadiazole amides
US4209623A (en)	1978-06-07	1980-06-24	Bristol-Myers Company	Pyrimidine-5-N-(1H-tetrazol-5-yl)-carboxamides
GB2063249A (en)	1979-10-09	1981-06-03	Mitsubishi Yuka Pharma	4-Phenylphthalazine derivatives
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US4912205A (en)	1986-03-20	1990-03-27	Daicel Chemical Industries, Ltd.	Alkyl-substituted phenylcarbamate derivative of polysaccharide
ES2031513T3 (es)	1986-08-21	1992-12-16	Pfizer Inc.	Quinazolindionas y piridopirimidinadionas.
CA1303037C (fr)	1987-02-02	1992-06-09	Smith Kline & French Laboratories Limited	Derives de purinone utilises comme bronchodilatateurs,vasodilatateurs et agents anti-allergiques
GB8814352D0 (en)	1988-06-16	1988-07-20	Smith Kline French Lab	Chemical compounds
EP0347146B1 (fr)	1988-06-16	1993-09-01	Smith Kline & French Laboratories Limited	Dérivés de pyrimidine condensés, procédé et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant
US5075310A (en)	1988-07-01	1991-12-24	Smith Kline & French Laboratories, Ltd.	Pyrimidone derivatives as bronchodilators
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8817651D0 (en)	1988-07-25	1988-09-01	Smith Kline French Lab	Chemical compounds
GB8827988D0 (en)	1988-11-30	1989-01-05	Smith Kline French Lab	Chemical compounds
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
GB8909560D0 (en)	1989-04-26	1989-06-14	Smith Kline French Lab	Chemical compounds
GB8923131D0 (en)	1989-10-13	1989-11-29	Smith Kline French Lab	Chemical compounds
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
GB9013750D0 (en)	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
US5401774A (en)	1991-03-08	1995-03-28	University Of Arizona	Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds
GB9114760D0 (en)	1991-07-09	1991-08-28	Pfizer Ltd	Therapeutic agents
PT100905A (pt)	1991-09-30	1994-02-28	Eisai Co Ltd	Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9121028D0 (en)	1991-10-03	1991-11-13	Pfizer Ltd	Therapeutic agents
GB9126260D0 (en)	1991-12-11	1992-02-12	Pfizer Ltd	Therapeutic agents
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5354571A (en)	1992-04-27	1994-10-11	Rheon Automatic Machinery Co., Ltd.	Method for aligning and bending individual round elongated dough pieces
US5243826A (en)	1992-07-01	1993-09-14	Apd Cryogenics Inc.	Method and apparatus for collecting liquid cryogen
JP2657760B2 (ja)	1992-07-15	1997-09-24	小野薬品工業株式会社	４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB9218322D0 (en)	1992-08-28	1992-10-14	Pfizer Ltd	Therapeutic agents
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
GB9312210D0 (en)	1993-06-14	1993-07-28	Smithkline Beecham Plc	Chemical compounds
US5698579A (en)	1993-07-02	1997-12-16	Celgene Corporation	Cyclic amides
CA2148260A1 (fr)	1993-09-10	1995-03-16	Yasutaka Takase	Composes a base de quinazoline
GB9514465D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Chemical compounds
GB9401090D0 (en)	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5608914A (en)	1994-11-21	1997-03-11	Keesler; Daren	Headcover
GB9423910D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
US5801195A (en)	1994-12-30	1998-09-01	Celgene Corporation	Immunotherapeutic aryl amides
US5703098A (en)	1994-12-30	1997-12-30	Celgene Corporation	Immunotherapeutic imides/amides
DE19501482A1 (de)	1995-01-19	1996-07-25	Bayer Ag	2,9-disubstituierte Purin-6-one
DE19501480A1 (de)	1995-01-19	1996-07-25	Bayer Ag	9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one
DE19501481A1 (de)	1995-01-19	1996-07-25	Bayer Ag	2,8-Disubstituierte Chinazolinone
US5488055A (en)	1995-03-10	1996-01-30	Sanofi Winthrop Inc.	Substituted N-cycloalkylmethyl-1H-pyrazolo(3,4-b)quinolin-4 amines and compositions and methods of use thereof
US5614530A (en)	1995-03-10	1997-03-25	Sterling Winthrop Inc.	Substituted N-arylmethyl and heterocyclmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines and compositions and methods of use thereof
ATE219765T1 (de)	1995-04-10	2002-07-15	Fujisawa Pharmaceutical Co	Indolderivate als cgmp-pde inhibitoren
TW381092B (en)	1995-07-07	2000-02-01	Otsuka Pharma Co Ltd	Novel benzimidazole derivatives for use in treating arteriosclerotic diseases
GB9514473D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Chemical compounds
GB9514464D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Medicaments
US5728844A (en)	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic agents
US5728845A (en)	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic nitriles
US5736537A (en)	1995-09-12	1998-04-07	Estee Lauder, Inc.	Dehydroep:androsterone sailcylate useful against skin atrophy
US5658940A (en)	1995-10-06	1997-08-19	Celgene Corporation	Succinimide and maleimide cytokine inhibitors
US6166041A (en)	1995-10-11	2000-12-26	Euro-Celtique, S.A.	2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
DE19540475A1 (de)	1995-10-20	1997-04-24	Schering Ag	Chirale Methylphenyloxazolidinone
US5710170A (en)	1995-12-15	1998-01-20	Merck Frosst Canada, Inc.	Tri-aryl ethane derivatives as PDE IV inhibitors
GB9526243D0 (en)	1995-12-21	1996-02-21	Celltech Therapeutics Ltd	Chemical compounds
GB9526245D0 (en)	1995-12-21	1996-02-21	Celltech Therapeutics Ltd	Chemical compounds
GB9526246D0 (en)	1995-12-21	1996-02-21	Celltech Therapeutics Ltd	Chemical compounds
WO1997024334A1 (fr)	1995-12-28	1997-07-10	Fujisawa Pharmaceutical Co., Ltd.	Derives du benzimidazole
GB9604926D0 (en)	1996-03-08	1996-05-08	Sandoz Ltd	Organic compounds
DE19617864A1 (de)	1996-04-23	1997-10-30	Schering Ag	Neue chirale Phenyldihydrofuranone
DE19632423A1 (de)	1996-08-12	1998-02-19	Merck Patent Gmbh	Thienopyrimidine
WO1998008848A1 (fr)	1996-08-30	1998-03-05	Kyowa Hakko Kogyo Co., Ltd.	Derives d'imidazoquinazoline
EP0989129B1 (fr)	1996-10-04	2002-12-11	Kyorin Pharmaceutical Co., Ltd.	Derives de pyrazolopyridylpyridazinone et procede de preparation des ces derniers
DE19642451A1 (de)	1996-10-15	1998-04-16	Merck Patent Gmbh	Aminothiophencarbonsäureamide
DE19644228A1 (de)	1996-10-24	1998-04-30	Merck Patent Gmbh	Thienopyrimidine
KR100239800B1 (ko)	1996-11-28	2000-03-02	손경식	4,5-디아미노 피리미딘 유도체 및 이의 제조방법
AU6230098A (en)	1997-02-27	1998-09-18	Tanabe Seiyaku Co., Ltd.	Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
DE59814173D1 (de)	1997-02-28	2008-04-03	Nycomed Gmbh	Synergistische kombination von pde-hemmern und adenylatcyclase-agonisten bzw. guanylcyclyse-agonisten
US6035089A (en) *	1997-06-11	2000-03-07	Lockheed Martin Energy Research Corporation	Integrated narrowband optical filter based on embedded subwavelength resonant grating structures
AU737008B2 (en)	1997-07-31	2001-08-09	Celgene Corporation	Substituted alkanohydroxamic acids and method of reducing TNFalpha levels
US6034089A (en)	1997-10-03	2000-03-07	Merck & Co., Inc.	Aryl thiophene derivatives as PDE IV inhibitors
US6020339A (en)	1997-10-03	2000-02-01	Merck & Co., Inc.	Aryl furan derivatives as PDE IV inhibitors
AU751453C (en)	1997-11-25	2003-04-10	Warner-Lambert Company	Benzenesulfonamide inhibitors of PDE-IV and their therapeutic use
US6020358A (en)	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels
US6025394A (en)	1999-01-29	2000-02-15	Cell Pathways, Inc.	Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
JP2002537383A (ja)	1999-02-25	2002-11-05	メルクフロストカナダアンドカンパニー	Ｐｄｅｉｖ阻害化合物、組成物および治療方法
US6316472B1 (en)	1999-05-13	2001-11-13	Merck Frosst Canada & Co.	Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6667316B1 (en) *	1999-11-12	2003-12-23	Celgene Corporation	Pharmaceutically active isoindoline derivatives
SE9904415D0 (sv)	1999-12-03	1999-12-03	Astra Ab	New process
PT1244649E (pt) *	1999-12-23	2005-06-30	Icos Corp	Inibidores de fosfodiesterase especificos de mfa ciclica
TR200201880T2 (tr)	2000-01-31	2002-11-21	Pfizer Products Inc.	PDE4 izozimerlerinin seçici önleyicileri olarak faydalı nikotinamit benzobağlı-heterosiklil türevleri
US7208516B2 (en) *	2002-03-20	2007-04-24	Celgene Corporation	Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en) *	2002-03-20	2007-10-02	Celgene Corporation	Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7123975B2 (en) *	2004-07-22	2006-10-17	Taiwan Semiconductor Manufacturing Co., Ltd.	Manufacturing management system and method
EP2007426A4 (fr)	2006-04-10	2010-06-16	Abbott Biotech Ltd	Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
WO2009011383A1 (fr)	2007-07-19	2009-01-22	Sekisui Chemical Co., Ltd.	Adhésif pour composant électronique
ES2442717T3 (es)	2008-01-18	2014-02-13	Atopix Therapeutics Limited	Compuestos que tienen actividad antagonista de CRTH2
PL2276483T3 (pl)	2008-03-27	2014-09-30	Celgene Corp	Stałe postacie zawierające (+)-2-[1-(3-etoksy-4-metoksyfenylo)-2-metylosulfonyloetylo]-4-acetyloaminoizoindolino-1,3-dion, kompozycje je zawierające i ich zastosowania
US20140004182A1 (en)	2009-11-19	2014-01-02	Jerome B. Zeldis	Methods for the treatment of sarcoidosis
AR081772A1 (es)	2010-06-02	2012-10-17	Ab Science	Tratamiento de la artritis reumatoide con masitinib

2003
- 2003-03-19 US US10/392,195 patent/US6962940B2/en not_active Expired - Lifetime
- 2003-03-20 EP EP10186076.5A patent/EP2311453B1/fr not_active Expired - Lifetime
- 2003-03-20 DK DK11176719.0T patent/DK2420490T3/en active
- 2003-03-20 KR KR1020107003988A patent/KR101104991B1/ko not_active Expired - Lifetime
- 2003-03-20 NZ NZ535798A patent/NZ535798A/en not_active IP Right Cessation
- 2003-03-20 KR KR1020047015190A patent/KR100997001B1/ko not_active Ceased
- 2003-03-20 EP EP11176719.0A patent/EP2420490B1/fr not_active Expired - Lifetime
- 2003-03-20 ES ES10162667T patent/ES2742729T3/es not_active Expired - Lifetime
- 2003-03-20 ES ES09003138.6T patent/ES2608495T3/es not_active Expired - Lifetime
- 2003-03-20 EP EP09003138.6A patent/EP2074995B1/fr not_active Revoked
- 2003-03-20 WO PCT/US2003/008738 patent/WO2003080049A1/fr not_active Ceased
- 2003-03-20 MX MXPA04009075A patent/MXPA04009075A/es active IP Right Grant
- 2003-03-20 DK DK10162653.9T patent/DK2223687T3/en active
- 2003-03-20 HU HUE10162667A patent/HUE045489T2/hu unknown
- 2003-03-20 HU HUE11176719A patent/HUE029682T2/en unknown
- 2003-03-20 PT PT101626539T patent/PT2223687T/pt unknown
- 2003-03-20 DK DK10162667.9T patent/DK2223688T3/da active
- 2003-03-20 PT PT10162667T patent/PT2223688T/pt unknown
- 2003-03-20 ES ES10186086.4T patent/ES2637509T3/es not_active Expired - Lifetime
- 2003-03-20 CN CN200910181158A patent/CN101683334A/zh active Pending
- 2003-03-20 PT PT101860864T patent/PT2295055T/pt unknown
- 2003-03-20 SI SI200332535T patent/SI2223687T1/sl unknown
- 2003-03-20 DK DK03721414T patent/DK1485087T3/da active
- 2003-03-20 MX MX2015010082A patent/MX366328B/es unknown
- 2003-03-20 SI SI200332599T patent/SI2223688T1/sl unknown
- 2003-03-20 JP JP2003577877A patent/JP2005525386A/ja active Pending
- 2003-03-20 EP EP15177140.9A patent/EP2962690B1/fr not_active Revoked
- 2003-03-20 CA CA2479666A patent/CA2479666C/fr not_active Expired - Fee Related
- 2003-03-20 ES ES15177140T patent/ES2717517T3/es not_active Expired - Lifetime
- 2003-03-20 ES ES03721414T patent/ES2331991T3/es not_active Expired - Lifetime
- 2003-03-20 EP EP10162667.9A patent/EP2223688B1/fr not_active Revoked
- 2003-03-20 SI SI200332591T patent/SI2962690T1/sl unknown
- 2003-03-20 HU HUE10186086A patent/HUE034348T2/hu unknown
- 2003-03-20 EP EP19151685.5A patent/EP3524242A1/fr not_active Withdrawn
- 2003-03-20 DK DK10186086.4T patent/DK2295055T3/en active
- 2003-03-20 DK DK15177140.9T patent/DK2962690T3/en active
- 2003-03-20 EP EP10162653.9A patent/EP2223687B1/fr not_active Revoked
- 2003-03-20 KR KR1020137021411A patent/KR20130100219A/ko not_active Ceased
- 2003-03-20 PT PT03721414T patent/PT1485087E/pt unknown
- 2003-03-20 EP EP03721414A patent/EP1485087B1/fr not_active Revoked
- 2003-03-20 SI SI200331659T patent/SI1485087T1/sl unknown
- 2003-03-20 HU HUE15177140A patent/HUE043539T2/hu unknown
- 2003-03-20 PT PT15177140T patent/PT2962690T/pt unknown
- 2003-03-20 EP EP10186086.4A patent/EP2295055B1/fr not_active Expired - Lifetime
- 2003-03-20 ES ES10186076.5T patent/ES2637547T3/es not_active Expired - Lifetime
- 2003-03-20 CA CA2756798A patent/CA2756798A1/fr not_active Abandoned
- 2003-03-20 AT AT03721414T patent/ATE440599T1/de active
- 2003-03-20 KR KR1020117003333A patent/KR20110022736A/ko not_active Ceased
- 2003-03-20 PT PT111767190T patent/PT2420490T/pt unknown
- 2003-03-20 DE DE60328974T patent/DE60328974D1/de not_active Expired - Lifetime
- 2003-03-20 CN CNB038110938A patent/CN100427085C/zh not_active Expired - Lifetime
- 2003-03-20 ES ES11176719.0T patent/ES2595375T3/es not_active Expired - Lifetime
- 2003-03-20 KR KR1020137004997A patent/KR101383845B1/ko not_active Expired - Lifetime
- 2003-03-20 IL IL16414703A patent/IL164147A0/xx unknown
- 2003-03-20 KR KR1020127000230A patent/KR101263786B1/ko not_active Expired - Lifetime
- 2003-03-20 ES ES10162653.9T patent/ES2635361T3/es not_active Expired - Lifetime
- 2003-03-20 AU AU2003224729A patent/AU2003224729C1/en active Active
- 2003-03-20 SI SI200332539T patent/SI2295055T1/sl unknown
2004
- 2004-09-20 IL IL164147A patent/IL164147A/en active Protection Beyond IP Right Term
2005
- 2005-04-13 US US11/106,142 patent/US7427638B2/en active Active
- 2005-06-28 US US11/170,308 patent/US7358272B2/en not_active Expired - Lifetime
2007
- 2007-06-29 US US11/824,523 patent/US7507759B2/en not_active Expired - Lifetime
2008
- 2008-02-08 US US12/069,282 patent/US7659302B2/en not_active Expired - Lifetime
- 2008-04-04 US US12/098,379 patent/US7659303B2/en not_active Expired - Lifetime
2009
- 2009-09-18 CY CY20091100967T patent/CY1109380T1/el unknown
- 2009-12-03 US US12/630,788 patent/US8455536B2/en not_active Expired - Fee Related
- 2009-12-28 JP JP2009297650A patent/JP2010106033A/ja active Pending
2010
- 2010-07-22 IL IL207149A patent/IL207149A/en active IP Right Review Request
2012
- 2012-11-02 JP JP2012242868A patent/JP5936521B2/ja not_active Expired - Lifetime
- 2012-11-20 US US13/682,652 patent/US8802717B2/en not_active Expired - Lifetime
2014
- 2014-06-26 US US14/316,160 patent/US9283207B2/en not_active Expired - Fee Related
- 2014-09-18 JP JP2014190477A patent/JP2015013893A/ja active Pending
2016
- 2016-02-05 US US15/016,856 patent/US9724330B2/en not_active Expired - Fee Related
2017
- 2017-06-21 US US15/629,678 patent/US10092542B2/en not_active Expired - Lifetime
- 2017-07-14 CY CY20171100748T patent/CY1119204T1/el unknown
- 2017-08-21 CY CY20171100884T patent/CY1119340T1/el unknown
2018
- 2018-09-07 US US16/125,571 patent/US10610516B2/en not_active Expired - Fee Related
2019
- 2019-04-03 CY CY20191100372T patent/CY1121720T1/el unknown
- 2019-06-14 LU LU00125C patent/LUC00125I2/fr unknown
- 2019-06-18 BE BE2019C008C patent/BE2019C008I2/nl unknown
- 2019-06-18 NL NL300994C patent/NL300994I2/nl unknown
- 2019-06-18 HU HUS1900032C patent/HUS1900032I1/hu unknown
- 2019-06-18 CY CY2019032C patent/CY2019032I1/el unknown
- 2019-07-12 FR FR19C1046C patent/FR19C1046I2/fr active Active
- 2019-08-14 CY CY20191100877T patent/CY1121888T1/el unknown
2020
- 2020-02-28 US US16/805,196 patent/US11040024B2/en not_active Expired - Fee Related
- 2020-08-26 US US17/003,238 patent/US11260046B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
KR101104991B1 (ko)	2012-01-16
EP2295055A3 (fr)	2011-03-23
US9283207B2 (en)	2016-03-15
US6962940B2 (en)	2005-11-08
JP5936521B2 (ja)	2016-06-22
SI2295055T1 (sl)	2017-10-30
DK2223687T3 (en)	2017-08-14
KR100997001B1 (ko)	2010-11-25
ES2595375T3 (es)	2016-12-29
US20200306226A1 (en)	2020-10-01
AU2003224729C9 (en)	2023-06-15
US20170281597A1 (en)	2017-10-05
DE60328974D1 (de)	2009-10-08
IL207149A (en)	2013-12-31
ES2717517T3 (es)	2019-06-21
EP2074995B1 (fr)	2016-11-02
WO2003080049A1 (fr)	2003-10-02
US8802717B2 (en)	2014-08-12
DK2223688T3 (da)	2019-08-19
JP2013047262A (ja)	2013-03-07
EP3524242A1 (fr)	2019-08-14
US20140024695A1 (en)	2014-01-23
SI2223687T1 (sl)	2017-10-30
PT2223688T (pt)	2019-09-05
AU2003224729C1 (en)	2025-01-23
DK2962690T3 (en)	2019-04-15
HK1073426A1 (en)	2005-10-07
US20080207730A1 (en)	2008-08-28
FR19C1046I1 (fr)	2019-08-09
EP2962690A1 (fr)	2016-01-06
PT1485087E (pt)	2009-10-23
LUC00125I1 (fr)	2019-06-18
KR20110022736A (ko)	2011-03-07
US11260046B2 (en)	2022-03-01
CY2019032I2 (el)	2020-05-29
HK1219049A1 (en)	2017-03-24
CN1652772A (zh)	2005-08-10
EP2420490B1 (fr)	2016-07-20
CN100427085C (zh)	2008-10-22
US20100160405A1 (en)	2010-06-24
US20050192336A1 (en)	2005-09-01
IL164147A (en)	2010-11-30
SI2223688T1 (sl)	2019-11-29
CY1109380T1 (el)	2014-07-02
ATE440599T1 (de)	2009-09-15
ES2635361T3 (es)	2017-10-03
DK2295055T3 (en)	2017-09-11
EP1485087B1 (fr)	2009-08-26
EP2311453B1 (fr)	2017-06-07
EP2223688A1 (fr)	2010-09-01
DK2420490T3 (en)	2016-10-03
ES2637509T3 (es)	2017-10-13
EP2223688B1 (fr)	2019-05-29
HK1103985A1 (en)	2008-01-04
US9724330B2 (en)	2017-08-08
KR20120024938A (ko)	2012-03-14
NZ535798A (en)	2006-04-28
KR20100040938A (ko)	2010-04-21
US20160151331A1 (en)	2016-06-02
JP2015013893A (ja)	2015-01-22
KR101263786B1 (ko)	2013-05-13
US7659302B2 (en)	2010-02-09
US7659303B2 (en)	2010-02-09
EP1485087A1 (fr)	2004-12-15
ES2637547T3 (es)	2017-10-13
CA2479666A1 (fr)	2003-10-02
EP2962690B1 (fr)	2019-01-16
US7507759B2 (en)	2009-03-24
DK1485087T3 (da)	2009-11-02
AU2003224729B2 (en)	2008-01-03
ES2742729T3 (es)	2020-02-17
US7427638B2 (en)	2008-09-23
PT2420490T (pt)	2016-10-12
JP2005525386A (ja)	2005-08-25
US8455536B2 (en)	2013-06-04
CA2756798A1 (fr)	2003-10-02
US20210023051A1 (en)	2021-01-28
CY1121720T1 (el)	2020-05-29
KR20050012722A (ko)	2005-02-02
US20080027123A1 (en)	2008-01-31
US10610516B2 (en)	2020-04-07
HUE029682T2 (en)	2017-02-28
FR19C1046I2 (fr)	2022-07-08
EP2295055A2 (fr)	2011-03-16
MX366328B (es)	2019-07-05
EP2311453A1 (fr)	2011-04-20
CY2019032I1 (el)	2020-05-29
NL300994I1 (nl)	2019-06-26
EP2223687B1 (fr)	2017-05-17
CA2479666C (fr)	2012-01-10
US20190000804A1 (en)	2019-01-03
US7358272B2 (en)	2008-04-15
HUS1900032I1 (hu)	2019-07-29
CN101683334A (zh)	2010-03-31
SI2962690T1 (sl)	2019-05-31
HUE045489T2 (hu)	2019-12-30
IL164147A0 (en)	2005-12-18
MXPA04009075A (es)	2005-07-13
CY1119340T1 (el)	2018-02-14
KR20130040257A (ko)	2013-04-23
KR20130100219A (ko)	2013-09-09
US20030187052A1 (en)	2003-10-02
US10092542B2 (en)	2018-10-09
PT2223687T (pt)	2017-07-25
EP2074995A1 (fr)	2009-07-01
EP2295055B1 (fr)	2017-06-07
CY1121888T1 (el)	2020-10-14
ES2608495T3 (es)	2017-04-11
KR101383845B1 (ko)	2014-04-10
AU2003224729A1 (en)	2003-10-08
BE2019C008I2 (fr)	2022-08-09
EP2223687A1 (fr)	2010-09-01
HUE034348T2 (hu)	2018-02-28
US11040024B2 (en)	2021-06-22
JP2010106033A (ja)	2010-05-13
SI1485087T1 (sl)	2009-12-31
CY1119204T1 (el)	2018-02-14
HUE043539T2 (hu)	2019-08-28
NL300994I2 (nl)	2019-07-11
PT2962690T (pt)	2019-04-30
US20140371287A1 (en)	2014-12-18
US20080242719A1 (en)	2008-10-02
EP2420490A1 (fr)	2012-02-22
PT2295055T (pt)	2017-08-29
US20050267196A1 (en)	2005-12-01
ES2331991T3 (es)	2010-01-22

Publication	Publication Date	Title
BE2019C008I2 (fr)	2022-08-09
MXPA05004778A (es)	2005-10-05	Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas.
TW200503784A (en)	2005-02-01	Organic compounds
WO2005105088A3 (fr)	2007-04-19	Procedes d'utilisation et compositions comportant des composes immunomodulateurs pour le traitement et le controle de l'hypertension pulmonaire
IL165264A (en)	2011-07-31	Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
WO2005044178A3 (fr)	2005-10-27	Procedes d'utilisation et compositions comprenant des composes immunomodulaires pour traiter, modifier et gerer la douleur
AU2003303633A8 (en)	2004-07-29	Fast dissolving films for oral administration of drugs
PL372457A1 (en)	2005-07-25	New pharmaceutical compositions containing flibanserin polymorph a
GB0109122D0 (en)	2001-05-30	Novel compounds
MY148125A (en)	2013-02-28	Compounds
MXPA06003122A (es)	2006-05-31	Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos.
MY136938A (en)	2008-11-28	New process for the synthesis of perindopril and its pharmaceutically acceptable salts
TW200503683A (en)	2005-02-01	Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
WO2005039497A3 (fr)	2005-10-20	Procedes et compositions a base de thalidomide pour le traitement des fibromyalgies
MY136288A (en)	2008-09-30	New process for the synthesis of perindopril and its pharmaceutically acceptable salts
MXPA05010070A (es)	2005-11-23	Combinacion farmaceutica.
MY149837A (en)	2013-10-31	New process for the synthesis of perindopril and pharmaceutically acceptable salts thereof
UA87292C2 (ru)	2009-07-10	Применение сирамезина для лечения злокачественных опухолей
MY137391A (en)	2009-01-30	New process for the synthesis of n-[(s)-1-ethoxycarbonylbutyl]-(s)-alanine and application in the synthesis of perindopril